Роль Е-кадхерина в неопластической эволюции эпителиальных клеток

Обложка

Цитировать

Полный текст

Аннотация

Трансмембранные белки кадхерины обеспечивают межклеточную адгезию через взаимодействие внеклеточных доменов. На протяжении многих лет эпителиальный Е-кадхерин считался опухолевым супрессором и рассматривался в качестве прогностического маркера у онкологических больных. Угнетение экспрессии Е-кадхерина наблюдали во многих карциномах. В последние несколько лет пересматриваются представления о супрессирующей оли Е-кадхерина. Показано, что протоковые карциномы молочной железы, карциномы толстой кишки, карциномы полости рта, плоскоклеточные карциномы головы и шеи могут сохранять экспрессию Е-кадхерина. При иммуногистохимическом окрашивании с использованием панели моноклональных антител во многих опухолях была выявлена мембранная локализация Е-кадхерина. В трансформированных эпителиоцитах in vitro были обнаружены динамичные межклеточные адгезионные контакты, образованные Е-кадхерином, которые важны для эффективной коллективной миграции клеток.

Об авторах

Н. А. Глушанкова

ФГБУ «РОНЦ им. Н. Н. Блохина» РАМН, Москва

Автор, ответственный за переписку.
Email: natglu@hotmail.com
Россия

И. Ю. Житняк

ФГБУ «РОНЦ им. Н. Н. Блохина» РАМН, Москва

Email: fake@neicon.ru
Россия

Д. В. Айолло

ФГБУ «РОНЦ им. Н. Н. Блохина» РАМН, Москва

Email: fake@neicon.ru
Россия

С. Н. Рубцова

ФГБУ «РОНЦ им. Н. Н. Блохина» РАМН, Москва

Email: fake@neicon.ru
Россия

Список литературы

  1. Meng W., Takeichi M. Adherens junction: molecular architecture and regulation. Cold Spring Harb Perspect Biol 2009;1:a002899.
  2. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006;127:469–80.
  3. Reynolds A.B., Daniel J., McCrea P.D. et al. Identification of a new catenin: the tyrosine kinase substrate p120cas associates with E-cadherin complexes. Mol Cell Biol 1994;14:8333–42.
  4. Ishiyama N., Lee S.H., Liu S. et al. Dynamic and static interactions between p120 catenin and E-cadherin regulate the stability of cell-cell adhesion. Cell 2010;141:117–28.
  5. Anastasiadis P.Z., Reynolds A.B. Regulation of Rho GTPases by p120-catenin; Curr Opin Cell Biol 2001;13:604–10.
  6. Van Roy F., Berx G. The cell–cell adhesion molecule E-cadherin. Cell Mol Life Sci 2008;65:3756–88.
  7. Cavallaro U., Christofori G. Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer 2004;4:118–32.
  8. Berx G., Van Roy F. Involvement of members of the cadherin superfamily in cancer. Cold Spring Harb Perspect Biol 2009;1:a003129.
  9. Berx G., Van Roy F. The E-cadherin/catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progression. Breast Cancer Res 2001;3: 289–93.
  10. Cowin P., Rowlands T.M., Hatsell S.J. Cadherins and catenins in breast cancer. Curr Opin Cell Biol 2005;17:499–508.
  11. Ling Z.Q., Li P., Ge M.H. et al. Hypermethylation-modulated downregulation of CDH1 expression contributes to the progression of esophageal cancer. Int J Mol Med 2011;27:625–35.
  12. Mayer B., Johnson J.P., Leitl F. et al. E-cadherin expression in primary and metastatic gastric cancer: down-regulation correlates with cellular dedifferentiation and glandular disintegration. Cancer Res 1993;53:1690–5.
  13. Zhai B., Yan H.X., Liu S.Q. et al. Reduced expression of E-cadherin/catenin complex in hepatocellular carcinomas. World J Gastroenterol 2008;14(37):5665–73.
  14. Schipper J.H., Frixen U.H., Behrens J. et al. E-cadherin expression in squamous cell carcinomas of head and neck: inverse correlation with tumor dedifferentiation and lymph node metastasis. Cancer Res 1991;51:6328–37.
  15. Bohm M., Totzeck B., Birchmeier W. et al. Differences of E-cadherin expression levels and patterns in primary and metastatic human lung cancer. Clin Exp Metastasis 1994;12:55–62.
  16. Umbas R., Schalken J.A., Aalders T.W. et al. Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res 1992;52:5104–9.
  17. Schuhmacher C., Becker I., Oswald S., et al. Loss of immunohistochemical E-cadherin expression in colon cancer is not due to structural gene alterations. Virchows Arch 1999;434:489–95.
  18. Hirohashi S. Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. Am J Pathol 1998;153:333–9.
  19. Heimann R., Lan F., McBride R. et al. Separating favorable from unfavorable prognostic markers in breast cancer: the role of E-cadherin. Cancer Res 2000;60:298–304.
  20. Perl A.K., Wilgenbus P., Dahl U. et al. A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature 1998;392:190–3.
  21. Behrens J., Mareel M.M., Van Roy F.M. et al. Dissecting tumor cell invasion: epithelial cells acquire invasive properties after the loss of uvomorulin-mediated cellcell adhesion. J Cell Biol 1989;108:2435–47.
  22. Frixen U.H., Behrens J., Sachs M. et al. E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol 1991;113:173–85.
  23. Luo J., Lubaroff D.M., Hendrix M.J. Suppression of prostate cancer invasive potential and matrix metalloproteinase activity by E-cadherin transfection. Cancer Res 1999;59:3552–6.
  24. Qian X., Karpova T., Sheppard A.M. et al. E-cadherin-mediated adhesion inhibits ligand-dependent activation of diverse receptor tyrosine kinases. EMBO J 2004;23:1739–48.
  25. Curto M., Cole B.K., Lallemand D. et al. Contact-dependent inhibition of EGFR signaling by Nf2/Merlin. J Cell Biol 2007;177:893–903.
  26. Kim N.G., Koh E., Chen X., Gumbiner B.M. E-cadherin mediates contact inhibition of proliferation through Hippo signalingpathway components. Proc Natl Acad Sci USA 2011;108:11930–5.
  27. Guarino M., Rubino B., Ballabio G. The role of epithelial-mesenchymal transition in cancer pathology. Pathology 2007;39(3):305–18.
  28. Huang R.Y., Guilford P., Thiery J.P. Early events in cell adhesion and polarity during epithelial-mesenchymal transition. Journal of Cell Science 2012;125(19):4417–22.
  29. Vasioukhin V. Adherens Junctions and Cancer; Harris T. (Ed.) Adherens Junctions: From Molecular Mechanisms to Tissue Development and Disease; Springer, 2012, VI, 379–413.
  30. Pinheiro H., Bordeira-Carriço R., Seixas S. et al. Allele-specific CDH1 downregulation and hereditary diffuse gastric cancer. Hum Mol Genet 2010;19:943–52.
  31. Elloul S., Elstrand M.B., Nesland J.M. et al. Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma. Cancer 2005;103:1631–43.
  32. Martin T.A., Goyal A., Watkins G. et al. Expression of the transcription factors snail, slug, and twist and their clinical significance in human breast cancer. Ann Surg Oncol 2005;12:488–96.
  33. Rosivatz E., Becker I., Specht K. et al. Differential expression of the epithelial-esenchymal transition regulators Snail, SIP1, and Twist in gastric cancer. Amer J Pathol 2002;161:1881–91.
  34. Spaderna S., Schmalhofer O., Wahlbuhl M. et al. The transcriptional repressor ZEB1 promotes metastasis and loss of cell polarity in cancer. Cancer Res 2008;68:537–44.
  35. Serrels A., Canel M., Brunton V.G. et al. Src/FAK-mediated regulation of E-cadherin as a mechanism for controlling collective cell movement. Insights from in vivo imaging. Cell Adh Migr 2011;5(4):360–5.
  36. Fujita Y., Krause G., Scheffner M. et al. Hakai, a c-Cbl-like protein, ubiquitinates and induces endocytosis of the E-cadherin complex. Nat Cell Biol 2002;4:222–31.
  37. Shen Y., Hirsch D.S., Sasiela C.A. et al. Cdc42 regulates E-cadherin ubiquitination and degradation through an epidermal growth factor receptor to Src-mediated pathway. J Biol Chem 2008;283:5127–37.
  38. Padua D., Massagué J. Roles of TGFbeta in metastasis. Cell Res 2009;19:89–102.
  39. Gomis R.R., Alarcon C., Nadal C. et al. C/EBPbeta at the core of the TGFbeta cytostatic response and its evasion in metastatic breast cancer cells. Cancer Cell 2006;10:203–14.
  40. Gillett C.E., Miles D.W., Ryder K. et al. Retention of the expression of E-cadherin and catenins is associated with shorter survival in grade III ductal carcinoma of the breast. J Pathol, 2001, 193, 33–41.
  41. Rakha E.A., Teoh T.K., Lee A.H.S. et al. Further evidence that E-cadherin is not a tumour suppressor gene in invasive ductal carcinoma of the breast: an immunohistochemical study. Histopathology 2013;62:695–701.
  42. Vered M., Allon I., Buchner A. et al. E-cadherin in oral SCC: An analysis of the confusing literature and new insights related to its immunohistochemical expression. Histol Histopathol 2012;27:141–50.
  43. de Moraes R.V., Oliveira D.T., Landman G. et al. E-cadherin abnormalities resulting from CPG methylation promoter in metastatic and nonmetastatic oral cancer. Head Neck 2008;30:85–92.
  44. Darai E., Scoazec J.Y., Walker-Combrouze F. et al. Expression of cadherins in benign, borderline, and malignant ovarian epithelial tumors: a clinicopathologic study of 60 cases. Hum Pathol 1997;28:922–8.
  45. Sundfeldt K., Piontkewitz Y., Ivarsson K. et al. E-cadherin expression in human epithelial ovarian cancer and normal ovary. Int J Cancer 1997;74:275–80.
  46. Hudson L.G., Zeineldin R., Stack M.S. Phenotypic Plasticity of Neoplastic Ovarian Epithelium: Unique Cadherin Profiles in Tumor Progression. Clin Exp Metastasis 2008;25(6):643–55.
  47. Kleer C.G., van Golen K.L., Braun T. et al. Persistent E-cadherin expression in inflammatory breast cancer. Mod Pathol 2001;14:458–64.
  48. Dong H.M., Liu G., Hou Y.F. et al. Dominant-negative E-cadherin inhibits the invasiveness of inflammatory breast cancer cells in vitro. J Cancer Res Clin Oncol 2007;133:83–92.
  49. Lewis-Tuffin L.J., Rodriguez F., Giannini C. et al. Misregulated E-cadherin expression associated with an aggressive brain tumor phenotype. PLoS One 2010;5:e13665.
  50. Rodriguez F.J., Lewis-Tuffin L.J., Anastasiadis P.Z. E-cadherin's dark side: Possible role in tumor progression. Biochimica et Biophysica Acta 2012;1826:23–31.
  51. Najy A.J., Day K.C., Day M.L. The ectodomain shedding of E-cadherin by ADAM15 supports ErbB receptor activation. J Biol Chem 2008;283:18393–401.
  52. Marambaud P., Shioi J., Serban G. et al. A presenilin-1/gamma-secretase cleavage releases the E-cadherin intracellular domain and regulates disassembly of adherens junctions. EMBO J 2002;21:1948–56.
  53. Friedl P., Locker J., Sahai E. et al. Classifying collective cancer cell invasion. Nat Cell Biol 2012;14(8):777–83.
  54. Nabeshima K., Inoue T., Shimao Y. et al. Cohort migration of carcinoma ells: differentiated colorectal carcinoma cells move as coherent cell clusters or sheets. Histol Histopathol 1999;14:1183–97.
  55. Hegerfeldt Y., Tusch M., Bröcker E.B. et al. Collective cell movement in primary melanoma explants: plasticity of cell-cell interaction, beta1-integrin function, and migration strategies. Cancer Res 2002;62:2125–30.
  56. Friedl P., Gilmour D. Collective cell migration in morphogenesis, regeneration and cancer. Nat Rev Mol Cell Biol 2009;10(7):445–57.
  57. Macpherson I.R., Hooper S., Serrels A. et al. p120-Catenin is required for the collective invasion of squamous cell carcinoma cells via a phosphorylationindependent mechanism. Oncogene 2007;26:5214–28.
  58. Vleminckx К., Vakaet L. Jr, Mareel M. et al. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell 1991;66:107– 19.
  59. Ayollo D.V., Zhitnyak I.Y., Vasiliev J.M. et al. Rearrangements of the actin cytoskeleton and E-cadherin–based adherens junctions caused by neoplasic transformation change cell–cell interactions. PLoS ONE 2009;4:1–17.
  60. Житняк И.Ю., Глушанкова Н.А. Особенности морфологии, межклеточных взаимодействий и миграционной активности эпителиоцитов IAR-2, трансформированных онкогеном RAS: вклад белка межклеточной адгезии Е-кадхерина. Онтогенез 2011;42:453–64.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ,


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 57560 от  08.04.2014.